Chordia Therapeutics (TSE:190A) NonCurrent Deferred Liabilities: 円0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
13 GF Score
Price 円80.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics NonCurrent Deferred Liabilities?

Chordia Therapeutics TSE:190A -2.44% 13 NonCurrent Deferred Liabilities is 円0.00 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Chordia Therapeutics's non-current deferred liabilities for the quarter that ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics NonCurrent Deferred Liabilities Related Terms

Chordia Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics NonCurrent Deferred Liabilities Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25 May25 Aug25 Nov25 Feb26 May26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:190A
13GF Score
Chordia Therapeutics Inc TSE:190A
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of 円0.00 Mil mean?
Chordia Therapeutics (TSE:190A) has a NonCurrent Deferred Liabilities of 円0.00 Mil as of Feb. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Chordia Therapeutics and its competitors.
Is Chordia Therapeutics' NonCurrent Deferred Liabilities too high?
Chordia Therapeutics' current NonCurrent Deferred Liabilities is 円0.00 Mil. Overall, Chordia Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Chordia Therapeutics' NonCurrent Deferred Liabilities of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Chordia Therapeutics and its competitors. Chordia Therapeutics's current NonCurrent Deferred Liabilities is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current NonCurrent Deferred Liabilities of 円0.00 Mil. The current NonCurrent Deferred Liabilities is 円0.00 Mil. Chordia Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current NonCurrent Deferred Liabilities is 円0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
13GF Score

Get the complete analysis for TSE:190A

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円80.00
Price